SCHEMBL31546447

SCHEMBL31546447

N#Cc1ccc(-c2noc(N3CCN(C(=O)NCCCN4CCC(Cc5ccccn5)CC4)CC3)n2)cc1

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ CCR3 P51677 3/20 0.46
▸ ALDH1A1 P00352 2/20 0.45
▸ LMNA P02545 2/20 0.45
▸ TP53 P04637 2/20 0.45
▸ HTT P42858 2/20 0.45
▸ SMN1; SMN2 Q16637 2/20 0.45
▸ TSHR P16473 1/20 0.45
▸ CHRM4 P08173 5/20 0.44
▸ MAPT P10636 2/20 0.42
▸ KDM4E B2RXH2 1/20 0.42
▸ HSD17B10 Q99714 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ GSK3B P49841 1/20 0.41
▸ HTR2A P28223 1/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ SLC6A2 P23975 1/20 0.40
▸ SLC6A4 P31645 1/20 0.40
▸ FAAH O00519 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30584882 0.90 LMNA (0.46) CCR3ALDH1A1LMNATP53HTT
SCHEMBL31546341 0.90 EPHX2 (0.49) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584895 0.88 LMNA (0.45) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584727 0.88 LMNA (0.47) CCR3ALDH1A1LMNATP53HTT
SCHEMBL31667543 0.88 LMNA (0.58) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584775 0.86 LMNA (0.49) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL30584805 0.86 LMNA (0.48) ALDH1A1LMNATP53HTTSMN1; SMN2
Formic Acid SCHEMBL31546410 0.86 LMNA (0.56) ALDH1A1LMNATP53HTTSMN1; SMN2
SCHEMBL31546418 0.78 LMNA (0.72) CCR3ALDH1A1LMNATP53HTT
SCHEMBL31667398 0.78 LMNA (0.55) ALDH1A1LMNATP53HTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP claimed
EP-4463452-B1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC (US) 2025-07-30 — — EP disclosed
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer ANIMA BIOTECH INC. (US) 2025-07-01 — — US disclosed
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER ANIMA BIOTECH INC. (US) 2025-04-03 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12344600-B2 c-Myc mRNA translation modulators and uses thereof in the treatment of cancer MYC, MYCBP, MYCBP2 CCR3 2847/4885ALDH1A1 4471/4885LMNA 1344/4885
US-20250109128-A1 C-MYC MRNA TRANSLATION MODULATORS AND USES THEREOF IN THE TREATMENT OF CANCER MYC, MYCBP, MYCBP2 CCR3 2847/4885ALDH1A1 4471/4885LMNA 1344/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback